Ashutosh Kumar1, Marilyn Ehrenshaft1, Erik J Tokar2, Ronald P Mason1, Birandra K Sinha3. 1. Immunity, Inflammation and Disease Laboratory, NIH, Research Triangle Park, North Carolina, USA. 2. National Toxicology Program National Institute of Environmental Health Sciences, NIH, Research Triangle Park, North Carolina, USA. 3. Immunity, Inflammation and Disease Laboratory, NIH, Research Triangle Park, North Carolina, USA. Electronic address: sinha1@niehs.nih.gov.
Abstract
BACKGROUND: Etoposide and doxorubicin, topoisomerase II poisons, are important drugs for the treatment of tumors in the clinic. Topoisomerases contain several free sulfhydryl groups which are important for their activity and are also potential targets for nitric oxide (NO)-induced nitrosation. NO, a physiological signaling molecule nitrosates many cellular proteins, causing altered protein and cellular functions. METHODS: Here, we have evaluated the roles of NO/NO-derived species in the activity/stability of topo II both in vitro and in human tumor cells, and in the cytotoxicity of topo II-poisons, etoposide and doxorubicin. RESULTS: Treatment of purified topo IIα with propylamine propylamine nonoate (PPNO), an NO donor, resulted in inhibition of both the catalytic and relaxation activity in vitro, and decreased etoposide-dependent cleavable complex formation in both human HT-29 colon and MCF-7 breast cancer cells. PPNO treatment also induced significant nitrosation of topo IIα protein in these human tumor cells. These events, taken together, caused a significant resistance to etoposide in both cell lines. However, PPNO had no effect on doxorubicin-induced cleavable complex formation, or doxorubicin cytotoxicity in these cell lines. CONCLUSION: Inhibition of topo II function by NO/NO-derived species induces significant resistance to etoposide, without affecting doxorubicin cytotoxicity in human tumor cells. GENERAL SIGNIFICANCE: As tumors express inducible nitric oxide synthase and generate significant amounts of NO, modulation of topo II functions by NO/NO-derived species could render tumors resistant to certain topo II-poisons in the clinic. Published by Elsevier B.V.
BACKGROUND: Etoposide and doxorubicin, topoisomerase II poisons, are important drugs for the treatment of tumors in the clinic. Topoisomerases contain several free sulfhydryl groups which are important for their activity and are also potential targets for nitric oxide (NO)-induced nitrosation. NO, a physiological signaling molecule nitrosates many cellular proteins, causing altered protein and cellular functions. METHODS: Here, we have evaluated the roles of NO/NO-derived species in the activity/stability of topo II both in vitro and in human tumor cells, and in the cytotoxicity of topo II-poisons, etoposide and doxorubicin. RESULTS: Treatment of purified topo IIα with propylamine propylamine nonoate (PPNO), an NO donor, resulted in inhibition of both the catalytic and relaxation activity in vitro, and decreased etoposide-dependent cleavable complex formation in both human HT-29 colon and MCF-7 breast cancer cells. PPNO treatment also induced significant nitrosation of topo IIα protein in these human tumor cells. These events, taken together, caused a significant resistance to etoposide in both cell lines. However, PPNO had no effect on doxorubicin-induced cleavable complex formation, or doxorubicin cytotoxicity in these cell lines. CONCLUSION: Inhibition of topo II function by NO/NO-derived species induces significant resistance to etoposide, without affecting doxorubicin cytotoxicity in human tumor cells. GENERAL SIGNIFICANCE: As tumors express inducible nitric oxide synthase and generate significant amounts of NO, modulation of topo II functions by NO/NO-derived species could render tumors resistant to certain topo II-poisons in the clinic. Published by Elsevier B.V.
Authors: Ian G Cowell; Zbyslaw Sondka; Kayleigh Smith; Ka Cheong Lee; Catriona M Manville; Malgorzata Sidorczuk-Lesthuruge; Holly Ashlene Rance; Kay Padget; Graham Hunter Jackson; Noritaka Adachi; Caroline A Austin Journal: Proc Natl Acad Sci U S A Date: 2012-05-21 Impact factor: 11.205
Authors: C A Felix; M R Hosler; D J Slater; R I Parker; M Masterson; J A Whitlock; T R Rebbeck; P C Nowell; B J Lange Journal: J Pediatr Hematol Oncol Date: 1998 Jul-Aug Impact factor: 1.289
Authors: Nilesh K Sharma; Ashutosh Kumar; Amrita Kumari; Erik J Tokar; Michael P Waalkes; Carl D Bortner; Jason Williams; Marilyn Ehrenshaft; Ronald P Mason; Birandra K Sinha Journal: PLoS One Date: 2015-11-05 Impact factor: 3.240
Authors: Simona Dostalova; Katerina Vasickova; David Hynek; Sona Krizkova; Lukas Richtera; Marketa Vaculovicova; Tomas Eckschlager; Marie Stiborova; Zbynek Heger; Vojtech Adam Journal: Int J Nanomedicine Date: 2017-03-24
Authors: Benjamin L Ricca; Gautham Venugopalan; Saori Furuta; Kandice Tanner; Walter A Orellana; Clay D Reber; Douglas G Brownfield; Mina J Bissell; Daniel A Fletcher Journal: Elife Date: 2018-03-21 Impact factor: 8.140
Authors: Birandra K Sinha; Carl D Bortner; Ronald P Mason; Ronald E Cannon Journal: Biochim Biophys Acta Gen Subj Date: 2018-09-01 Impact factor: 3.770